Alternatively spliced tissue factor synergizes with the estrogen receptor pathway in promoting breast cancer progression

J Thromb Haemost. 2015 Sep;13(9):1683-93. doi: 10.1111/jth.13049. Epub 2015 Jul 31.

Abstract

Background: Procoagulant full-length tissue factor (flTF) and its minimally coagulant alternatively spliced isoform (asTF), promote breast cancer (BrCa) progression via different mechanisms. We previously showed that flTF and asTF are expressed by BrCa cells, resulting in autoregulation in a cancer milieu. BrCa cells often express hormone receptors such as the estrogen receptor (ER), leading to the formation of hormone-regulated cell populations.

Objective: To investigate whether TF isoform-specific and ER-dependent pathways interact in BrCa.

Methods: Tissue factor isoform-regulated gene sets were assessed using ingenuity pathway analysis. Tissues from a cohort of BrCa patients were divided into ER-positive and ER-negative groups. Associations between TF isoform levels and tumor characteristics were analyzed in these groups. BrCa cells expressing TF isoforms were assessed for proliferation, migration and in vivo growth in the presence or absence of estradiol.

Results: Ingenuity pathway analysis pointed to similarities between ER- and TF-induced gene expression profiles. In BrCa tissue specimens, asTF expression was associated with grade and stage in ER-positive but not in ER-negative tumors. flTF was only associated with grade in ER-positive tumors. In MCF-7 cells, asTF accelerated proliferation in the presence of estradiol in a β1 integrin-dependent manner. No synergy between asTF and the ER pathway was observed in a migration assay. Estradiol accelerated the growth of asTF-expressing tumors but not control tumors in vivo in an orthotopic setting.

Conclusion: Tissue factor isoform and estrogen signaling share downstream targets in BrCa; the concomitant presence of asTF and estrogen signaling is required to promote BrCa cell proliferation.

Keywords: blood coagulation; cell movement; cell proliferation; integrin beta1; tumors.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alternative Splicing*
  • Breast Neoplasms / genetics
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / pathology*
  • Carcinoma / genetics
  • Carcinoma / metabolism
  • Carcinoma / pathology*
  • Cell Division / drug effects
  • Cell Line, Tumor
  • Cell Movement / drug effects
  • Disease Progression
  • Estradiol / pharmacology
  • Estrogens*
  • Female
  • Gene Expression Profiling
  • Humans
  • Integrin beta1 / physiology
  • Neoplasm Grading
  • Neoplasm Proteins / genetics
  • Neoplasm Proteins / physiology*
  • Neoplasm Staging
  • Neoplasms, Hormone-Dependent / genetics
  • Neoplasms, Hormone-Dependent / metabolism
  • Neoplasms, Hormone-Dependent / pathology*
  • Protein Isoforms / genetics
  • Protein Isoforms / physiology
  • Receptors, Estrogen / physiology*
  • Signal Transduction / physiology*
  • Software
  • Thromboplastin / genetics
  • Thromboplastin / physiology*
  • Tissue Array Analysis

Substances

  • Estrogens
  • Integrin beta1
  • Neoplasm Proteins
  • Protein Isoforms
  • Receptors, Estrogen
  • Estradiol
  • Thromboplastin